CurrentKaiser PermanentePolicy N/A

Fundoplication Surgery & Treatment of Gastroesophageal Reflux Disease

Clinical review criteria for multiple surgical and endoscopic treatments for GERD (fundoplication, LINX, Stretta, EsophyX/TIF, endoscopic bulking agents, EndoCinch/Bard suturing, etc.) covering Medicare and non‑Medicare members; defines indications, required prior documentation, references to MCG guidelines, and technology assessments for investigational/insufficient-evidence services. This is part 1 of 2.

Policy Summary

PayerKaiser Permanente

PolicyFundoplication Surgery & Treatment of Gastroesophageal Reflux Disease

Policy CodePolicy N/A

Change TypeAdoption of limited criteria; coverage revisions

Effective DateJan 1, 2025

Next Review DateSep 2, 2025

Key ActionSubmit last 6 months of clinical notes from requesting provider and/or specialist to support medical necessity.

SourceLink

POLICY UPDATE CHANGES

12/03/2024 MPC approved to adopt limited criteria for EsophyX and LINX procedures; 60-day notice required, effective 1/2025 May.

09/03/2024 MPC approved to adopt coverage for Fundoplication surgery using a hybrid guideline, KP-S-505.

07/08/2019 MTAC review added Magnetic Sphincter Augmentation (LINX) assessment; previously not meeting MTAC criteria.

MultipleCovered/Assessed Indications

3Procedure groups Covered with criteria

2Device procedures with limited/conditional coverage

3Procedures Not Medically Necessary

Not coveredMCG Outcome - Stretta

Coverage Summary

Policy: Fundoplication Surgery & Treatment of Gastroesophageal Reflux Disease (GERD). Effective 2025-01-01; last reviewed 2024-12-03; next review 2025-09-02. Coverage stance: mixed—some surgical fundoplication approaches are covered with criteria, certain device-based procedures have conditional or limited coverage, and several endoluminal therapies are considered not medically necessary or investigational.

Covered procedures with clinical criteria: laparoscopic, transthoracic, and abdominal fundoplication and hiatal hernia repair are medically necessary when policy clinical criteria and Level of Care Review requirements are met. LINX (magnetic sphincter augmentation) is medically necessary when specified LINX criteria are met (limited criteria adopted per 12/03/2024).

Conditional/limited coverage: Transoral incisionless fundoplication (TIF/EsophyX) and LINX have had evolving, limited criteria and conditional coverage actions; MCG or Kaiser criteria apply for determinations. Not covered / investigational: Stretta (radiofrequency delivery), endoscopic bulking agents, CR BARD EndoCinch/endoscopic suturing, and other endoluminal plication/fastener devices are designated not medically necessary or investigational due to insufficient evidence.

Key thresholds / level-of-care

Adequate trial of medical therapyAt least 4 concurrent months of proton pump inhibitor (PPI) use

Hiatal hernia size exclusion for TIF> 2 cm

Barrett's esophagus exclusion for TIF> 2 cm

BMI exclusion for TIF> 35

Level of Care Review requiredElective fundoplication procedures require Level of Care Review per KP (use KP-S-505 MCG guideline)

Medical Necessity Criteria (by procedure/tech)

Implantable Magnetic Esophageal Ring (LINX) - Non‑Medicare criteria

Implantable Magnetic Esophageal Ring (LINX) — Non‑Medicare criteria. Procedure is indicated for typical symptomatic GERD (e.g., heartburn, regurgitation, dental erosions) when ALL of the following are met and the listed exclusions are absent:

ALL of the following

Typical symptomatic GERD (e.g., heartburn, regurgitation, dental erosions).
Confirmation of diagnosis by endoscopy, ambulatory pH monitoring, or barium swallow study.
Unresponsive to lifestyle modification (see definitions).
Failure, contraindication, or intolerance of an adequate trial of medical therapy (see definitions).

Not Medically Necessary / Experimental Procedures

MTAC and historical evidence reviews categorized several endoluminal devices and procedures as experimental/insufficient evidence. For TIF (EsophyX), MTAC concluded RCTs compared TIF to sham or PPI but not to laparoscopic Nissen fundoplication; indirect comparisons suggest inferior objective acid control and uncertain long-term benefit, with efficacy that may decline over time.

For the LINX Reflux Management System, MTAC reviews (2014 and subsequent assessments) found insufficient evidence—no RCTs versus Nissen and uncertainty about long-term safety and effectiveness; earlier MTAC determinations did not meet Kaiser MTAC criteria.

Endoluminal fasteners (StomaphyX, InScope) and endoscopic fastener/plication systems were judged to have insufficient published evidence to determine efficacy or safety. MTAC cited lack of published studies and reliance on manufacturer information as rationale.

Common rationales across these MTAC findings included limited or low-quality evidence, short follow-up durations, operator dependence/steep learning curves, and lack of direct comparisons to gold-standard surgical fundoplication.

Coding

LINX Placement/RemovalCPTCovered

43284	Laparoscopy, surgical, esophageal sphincter augmentation procedure, placement of sphincter augmentation device (ie, magnetic band), including cruroplasty when performed
43285	Removal of esophageal sphincter augmentation device

Stretta (Not Medically Necessary)CPTNot Covered

43257

Esophagogastroduodenoscopy, flexible, transoral; with delivery of thermal energy to the muscle of lower esophageal sphincter and/or gastric cardia, for treatment of gastroesophageal reflux disease

TIF/EsophyX (Coverage conditional)CPTExperimental

43210

Esophagogastroduodenoscopy, flexible, transoral; with esophagogastric fundoplasty, partial or complete, includes duodenoscopy when performed

Endoscopic bulking material (Not Medically Necessary)CPTNot Covered

43192	Esophagoscopy, rigid, transoral; with directed submucosal injection(s), any substance
43201	Esophagoscopy, flexible, transoral; with directed submucosal injection(s), any substance

Endoscopic suturing system (Not Medically Necessary)CPTNot Covered

No codes listed

Laparoscopic Fundoplication and Hiatal Hernia Repair (Medically Necessary)CPTCovered

43280	Laparoscopy, surgical, esophagogastric fundoplasty (eg, Nissen, Toupet procedures)
43281	Laparoscopy, surgical, repair of paraesophageal hernia, includes fundoplasty, when performed; without implantation of mesh
43282	Laparoscopy, surgical, repair of paraesophageal hernia, includes fundoplasty, when performed; with implantation of mesh

Transthoracic Fundoplication (Medically Necessary)CPTCovered

43325	Esophagogastric fundoplasty with fundic patch Thal-Nissen procedure
43328	Esophagogastric fundoplasty partial or complete; thoracotomy
43334	Repair, paraesophageal hiatal hernia (including fundoplication), via thoracotomy, except neonatal; without implantation of mesh
43335	Repair, paraesophageal hiatal hernia (including fundoplication), via thoracotomy, except neonatal; with implantation of mesh or other prosthesis
43336	Repair, paraesophageal hiatal hernia (including fundoplication), via thoracoabdominal incision, except neonatal; without implantation of mesh or other prosthesis
43337	Repair, paraesophageal hiatal hernia (including fundoplication), via thoracoabdominal incision, except neonatal; with implantation of mesh or other prosthesis

Abdominal Fundoplication (Medically Necessary)CPTCovered

43327	Esophagogastric fundoplasty partial or complete; laparotomy
43333	Repair, paraesophageal hiatal hernia (including fundoplication), via laparotomy, except neonatal; with implantation of mesh or other prosthesis

Provider Actions & Authorization Requirements

Prior Authorization

Level of Care Review required for fundoplication

Elective surgical Level of Care Review is required for fundoplication procedures. Verify that an approved Level of Care Review (prior authorization) is in place before scheduling elective fundoplication surgery. Use the Pre-authorization Code Check to confirm authorization status with the member's plan.

Affected codes: CPT 43280 (Esophagogastric fundoplasty, laparoscopic), CPT 43281 (Repair of paraesophageal hernia, laparoscopic, with fundoplication), CPT 43324 (Repair of hiatal hernia, laparoscopic, with fundoplication)

Documentation Required

Required documentation for service request

Required documentation must be submitted to support the service request. Include clinical rationale, prior treatments, and recent diagnostic findings. Submit the last 6 months of clinical notes from the requesting provider and/or specialist (gastroenterologist or general surgeon).

Background & Evidence Summary

GERD is a common chronic disorder characterized primarily by heartburn and regurgitation arising from transient relaxation or low resting pressure of the lower esophageal sphincter (LES); prevalence in Western populations is estimated at roughly 10–20%. Complications include esophagitis and Barrett's esophagus, and symptoms can substantially impair quality of life.

Medical therapy centers on proton pump inhibitors (PPIs) which suppress gastric acid production but do not correct LES dysfunction; up to about 40% of patients have partial or no response to PPIs and may remain symptomatic or have endoscopic disease despite therapy.

Surgical and endoscopic alternatives include: Nissen fundoplication (laparoscopic fundoplication) which reconstructs the LES and is an established effective surgical option but is technically demanding and associated with side effects (dysphagia, bloating, inability to belch/vomit); magnetic sphincter augmentation (LINX) — a laparoscopically implanted ring of interlinked magnetic beads that augments the LES and received FDA approval in 2012; radiofrequency application (Stretta) which delivers RF energy to LES muscle to induce localized scarring and tightening; transoral incisionless fundoplication (TIF/EsophyX) which uses transmural fasteners to recreate a gastroesophageal valve; endoscopic suturing systems (EndoCinch/CR Bard) that plicate tissue; and endoscopic bulking/injection agents intended to bulk the LES.

Device mechanisms and regulatory context: LINX is an FDA‑approved magnetic sphincter augmentation device (FDA approval March 22, 2012). Stretta (Curon CSM Stretta System) was FDA cleared in 2000 as an RF system. EsophyX received 510(k) clearance for endoluminal full‑thickness plication and to reduce small hiatal hernias (<2 cm); multiple generations of EsophyX and TIF techniques exist. Endoscopic suturing (EndoCinch, ESD) received prior FDA approvals, while many bulking agents and some plication devices remain investigational or had limited/short-term evidence.

Evidence Source	Summary/Outcome
LINX MTAC review (12/15/2014)
Insufficient evidence to support effectiveness or safety; does not meet Kaiser Medical Technology Assessment Criteria.
Stretta MTAC review (12/10/2003 and later updates)
Insufficient evidence; MCG guideline indicates service is not covered; studies limited and follow-up short.
EndoCinch/Bard and bulking materials (02/13/2003)
Insufficient evidence; does not meet MTAC criteria; limited case series and short follow-up.
MTAC conclusion (07/13/2020) - TIF (EsophyX)
Insufficient published evidence to determine net health outcomes vs laparoscopic Nissen; may improve subjective QoL vs sham but not objective measures; efficacy may decrease over time.
MTAC conclusion (07/08/2019) - LINX (additional)
Low-quality evidence suggests improved ability to belch/vomit and less bloating vs fundoplication; no RCTs vs Nissen; insufficient long-term evidence.
Hayes assessment (04/21/2023)
Hayes technology assessment on laparoscopic surgery for refractory GERD referenced as guideline-level support for fundoplication.

Medicare Determinations & Guideline References

Medicare determinations and guideline use: There is no single active NCD/LCD covering many of these procedures; where Medicare guidance is absent Kaiser elects to apply its non‑Medicare clinical review criteria. Kaiser references MCG care guidelines for determinations—specifically A-0209 (Stretta) and KP-S-505 (Fundoplication and Hiatal Hernia Repair)—and defers to those MCG outcomes for medical necessity.

MCG guidance outcome: Stretta determinations follow MCG A-0209, and MCG indicates this service is not covered. Kaiser also uses MCG KP-S-505 for fundoplication level-of-care and medical necessity reviews.

LINX Medicare note: Medicare coverage for the LINX Reflux Management System was added on 2016-07-21, and Kaiser’s policy history records that LINX Medicare coverage was incorporated on that date; otherwise Kaiser has historically noted MTAC conclusions of insufficient evidence for LINX prior to later limited-criteria adoption.

Medicare / LCD / NCD entries

NCD/LCD statusNo active NCD/LCD for many GERD procedures; Kaiser uses non‑Medicare criteria where NCD/LCD absent.

Stretta / MCG A-0209Kaiser elected to use MCG guideline A-0209 for Stretta; MCG indicates this service is not covered.

Fundoplication / KP-S-505

Revision History

12/03/2024policy_adoptionLatest

MPC approved adoption of limited criteria for EsophyX (TIF) and LINX (MSA) procedures; 60-day notice required, effective May 2025.

09/03/2024policy_revision

MPC approved adoption of coverage for Fundoplication surgery using a hybrid guideline (KP-S-505).

07/08/2019mtac_review

MTAC review added an assessment of Magnetic Sphincter Augmentation (LINX); MTAC concluded there was insufficient evidence (low-quality short-term evidence) and it did not meet MTAC criteria at that time.

Policy Summary

PayerKaiser Permanente

PolicyFundoplication Surgery & Treatment of Gastroesophageal Reflux Disease

Policy CodePolicy N/A

Change TypeAdoption of limited criteria; coverage revisions

Effective DateJan 1, 2025

Next Review DateSep 2, 2025

Key ActionSubmit last 6 months of clinical notes from requesting provider and/or specialist to support medical necessity.

SourceLink

On This Page

Documentation supports need for LINX versus traditional fundoplication procedures.

Exclusions must be absent

Complete failure of the lower esophageal sphincter.
Dysphagia.
Previous endoluminal anti-reflux procedure.
Barrett's esophagus.

Note: Definitions — Lifestyle modifications include weight loss, avoidance of trigger foods, avoidance of late meals, and elevation of the head of the bed. Failure is lack of response or inadequate response with significant residual functional limitations; an adequate trial of medical therapy would be at least 4 months of concurrent PPI use.

Transoral incisionless fundoplication (TIF / EsophyX) - Non‑Medicare criteria

Transoral incisionless fundoplication (TIF / EsophyX) — Non‑Medicare criteria. Procedure is indicated for typical symptomatic GERD when ALL of the following are met and the following exclusions are not present:

ALL of the following

Typical symptomatic GERD (e.g., heartburn, regurgitation, dental erosions).
Confirmation of diagnosis by endoscopy, ambulatory pH monitoring, or barium swallow study.
Unresponsive to lifestyle modification (see definitions).
Failure, contraindication, or intolerance of an adequate trial of medical therapy (an adequate trial = at least 4 months of concurrent PPI use).
Exclusions — procedure is NOT indicated if any of the following are present
- Prior transoral incisionless fundoplication (TIF).
- Hiatal hernia greater than 2 cm.
- Esophagitis LA grade > B.
- Barrett's esophagus > 2 cm.
- Achalasia.
- Esophageal ulcer.
- Body mass index (BMI) > 35.

Note: Lifestyle modifications include weight loss, avoidance of trigger foods, avoidance of late meals, and elevation of the head of the bed. Failure is defined as lack of response or inadequate response with significant residual functional limitations due to symptoms.

Medically Necessary - Laparoscopic/Transthoracic/Abdominal Fundoplication and Hiatal Hernia Repair

Medically Necessary — Laparoscopic/Transthoracic/Abdominal Fundoplication and Hiatal Hernia Repair. Requires Level of Care Review and that members meet the applicable policy clinical criteria.

ALL of the following

Request undergoes Level of Care Review per plan requirements.
Member meets the applicable clinical criteria in the Fundoplication and Hiatal Hernia Repair policy and the MCG* Care Guideline used by Kaiser Permanente for medical necessity determinations (refer to KP policy references).
Documentation submitted to support medical necessity (see documentation guidance).

Operational note: Kaiser Permanente has elected to use the Fundoplication and Hiatal Hernia Repair, by Laparoscopy (KP-S-505 02012025) MCG Care Guideline for determinations; follow Level of Care Review process for Medicare and Non‑Medicare members as specified in the policy header.

Medically Necessary - LINX Reflux Management System (Magnetic Sphincter Augmentation)

Medically Necessary — LINX Reflux Management System (Magnetic Sphincter Augmentation). Member must meet the specified criteria in this policy (see the LINX Non‑Medicare criteria above and applicable policy statements).

ALL of the following

Member meets the LINX-specific non‑Medicare eligibility criteria specified elsewhere in this policy (typical symptomatic GERD, objective confirmation, failure of lifestyle/medical therapy, and documentation supporting LINX vs fundoplication).
Absence of listed exclusions for LINX (see Implantable Magnetic Esophageal Ring criteria group).
For Medicare members, defer to applicable KP Medical Policy statements and Level of Care Review as noted in the policy header.

Operational note: Refer to the LINX criteria group within this document for the full list of required elements and exclusions; ensure prior authorization/Level of Care Review documentation is complete.

Radiofrequency Energy Delivery to Gastroesophageal Junction (Stretta)

Radiofrequency Energy Delivery to Gastroesophageal Junction (Stretta). Kaiser Permanente has elected to use the referenced MCG Care Guideline for medical necessity determinations.

ALL of the following

Kaiser Permanente uses the Radiofrequency Energy Delivery to Gastroesophageal Junction (Stretta) (A-0209) MCG Care Guideline for determinations.
Per MCG guideline, the Stretta procedure is not covered (not medically necessary) under the guideline's indications and outcomes.
Application by payer type
- For Medicare members: in the absence of an active NCD/LCD, use the non‑Medicare Clinical Review Criteria unless otherwise specified; Kaiser Permanente defers to the MCG guideline which indicates not covered.
- For Non‑Medicare members: Kaiser Permanente uses the MCG guideline (Stretta not covered) for medical necessity determinations; individual case-level criteria may be requested via Level of Care Review and MCG rationale can be provided on request.

Operational note: The MCG manuals are proprietary; providers may request the specific MCG criteria used in an individual utilization management decision by contacting Kaiser Permanente Clinical Review staff.

Endoscopic Placement of Bulking Material / Endoscopic injection of bulking agents

Endoscopic Placement of Bulking Material / Endoscopic injection of bulking agents — Insufficient evidence (investigational).

ALL of the following

There is insufficient evidence in the published medical literature to show that endoscopic placement of bulking material at the lower esophageal sphincter or endoscopic injection of bulking agents (e.g., Durasphere, pyrolytic carbon-coated zirconium oxide spheres, polymethylmethacrylate beads, Enteryx, Gatekeeper) is as safe and effective as standard therapies.
These procedures are considered investigational / not medically necessary due to inadequate evidence of long-term outcomes compared with standard surgical or medical management.

Operational note: For Medicare members, in the absence of an active NCD/LCD these services are evaluated using the plan's Clinical Review Criteria of insufficient evidence; for Non‑Medicare members the same investigational stance applies. Providers may submit requests with supporting documentation but should expect these services to be denied as investigational unless new evidence is provided.

CR BARD's Endoscopic Suturing System (EndoCinch) and other endoluminal plication devices

CR BARD's Endoscopic Suturing System (EndoCinch) and other endoluminal plication devices — MTAC / assessment conclusion: insufficient evidence (not meeting MTAC).

ALL of the following

Endoscopic suturing and endoluminal plication devices (examples: EndoCinch, Plicator, StomaphyX, Endoscopic suturing systems) have been assessed and the Medical Technology Assessment Committee (MTAC) or equivalent review determined there is insufficient evidence to conclude these therapies provide durable benefit equal to or better than standard surgical therapies.
Consequently, these devices/procedures are considered investigational / not medically necessary under current policy.

Operational note: This MTAC conclusion is consolidated into the policy's Experimental / Insufficient Evidence grouping. Providers should not expect coverage for CR BARD's EndoCinch or similar endoluminal plication procedures; submit supporting clinical documentation if requesting an exception and the MTAC rationale may be provided on request.

Documentation Required

Diagnostics required prior to LINX/TIF

For consideration of LINX or transoral incisionless fundoplication (TIF/EsophyX), confirmation of GERD diagnosis is required prior to authorization. Required diagnostic confirmation includes endoscopy, ambulatory pH monitoring, or a barium swallow study; documentation must clearly demonstrate one of these confirming studies.

Prior Authorization

MCG guideline use for Stretta

MCG guideline A-0209 (Radiofrequency Energy Delivery to Gastroesophageal Junction — Stretta) is used for medical necessity determinations for Stretta. Per MCG A-0209, the Stretta procedure is not covered; determinations for Stretta will defer to MCG guidance.

Documentation Required

Apply applicable policy clinical criteria

Apply the applicable policy clinical criteria for the specific procedure requested. Providers must document that members meet the procedure-specific clinical criteria (e.g., LINX, traditional fundoplication, TIF) including diagnosis confirmation, failure or contraindication to adequate medical therapy, and absence of exclusionary conditions.

Definitions (quick reference)

Lifestyle ModificationsWeight loss, avoidance of trigger foods, avoidance of late meals, and elevation of the head of the bed.

Failure of medical therapyLack of response to conservative therapy or inadequate response with significant residual functional limitations; adequate trial = ≥4 concurrent months of PPI use.

Paraoesophageal HerniaA true hernia with a hernia sac composed of peritoneum characterized by upward dislocation of the gastric fundus through a focal defect in the phrenoesophageal membrane (see Type II-IV).

TIFTransoral incisionless fundoplication (eg, EsophyX system).

MSA / LINXMagnetic sphincter augmentation using the LINX Reflux Management System.

StrettaTransesophageal radiofrequency energy delivery to the lower esophageal sphincter/gastric cardia.

Kaiser elected to use Fundoplication and Hiatal Hernia Repair, by Laparoscopy (KP-S-505) MCG Care Guideline; elective fundoplication requires Level of Care Review.

LINX Medicare coverage noteLINX Medicare coverage added 07/21/2016 (recorded in revision history).